Literature DB >> 15763746

The 'co-morbidity roundabout': a framework to guide assessment and intervention strategies and engineer change among people with co-morbid problems.

Frances J Kay-Lambkin1, Amanda L Baker, Terry J Lewin.   

Abstract

This paper describes the nature and consequences of co-morbidity, as applied to co-occurring mental health and alcohol/other drug (AOD) use problems. The 'co-morbidity roundabout' is introduced as a useful metaphor for conceptualizing the current experiences of people with co-occurring mental health and AOD use problems. In order to successfully negotiate the 'roundabout', the 'drivers' (people with co-morbid mental health and AOD use problems) must consider a range of internal and external conditions (knowledge about services, support from family, friends, health providers, motivation to change, etc.), account for their vehicle's characteristics (other conditions and demands, including social/legal/financial issues), keep their travel itinerary in mind (plans for change including treatment) and navigate through the many detours and dead-ends that they may confront (eligibility for services, accessibility of treatments, etc.). Co-morbidity is a major contributing factor in 'drivers' failing to successfully negotiate, or even becoming 'stuck' on, the 'roundabout'. A summary of relevant treatment research is also presented, including descriptions of brief interventions and more intensive treatment approaches. Finally, the 'co-morbidity roundabout' metaphor is expanded to assist clinicians to translate the findings from this treatment research into clinical practice. Further suggestions are made for improved navigation through and exit from the 'roundabout', including recommendations for the use of a stepped-care approach to the assessment and treatment of clients with co-morbid mental health and AOD use problems.

Entities:  

Mesh:

Year:  2004        PMID: 15763746     DOI: 10.1080/09595230412331324536

Source DB:  PubMed          Journal:  Drug Alcohol Rev        ISSN: 0959-5236


  8 in total

Review 1.  Treatment of substance abusing patients with comorbid psychiatric disorders.

Authors:  Thomas M Kelly; Dennis C Daley; Antoine B Douaihy
Journal:  Addict Behav       Date:  2011-09-14       Impact factor: 3.913

2.  Intensive motivational interviewing for women with concurrent alcohol problems and methamphetamine dependence.

Authors:  Rachael A Korcha; Douglas L Polcin; Kristy Evans; Jason C Bond; Gantt P Galloway
Journal:  J Subst Abuse Treat       Date:  2013-09-26

3.  Factors Associated with Perceived Continuity of Care Among Patients Suffering from Mental Disorders.

Authors:  Claudie Loranger; Marie-Josée Fleury
Journal:  Community Ment Health J       Date:  2019-12-20

4.  Study protocol: a dissemination trial of computerized psychological treatment for depression and alcohol/other drug use comorbidity in an Australian clinical service.

Authors:  Frances J Kay-Lambkin; Amanda L Baker; Alison Healey; Samantha Wolfe; Aaron Simpson; Michelle Brooks; Jenny Bowman; Steven Childs
Journal:  BMC Psychiatry       Date:  2012-07-07       Impact factor: 3.630

5.  Acceptability of a clinician-assisted computerized psychological intervention for comorbid mental health and substance use problems: treatment adherence data from a randomized controlled trial.

Authors:  Frances Kay-Lambkin; Amanda Baker; Terry Lewin; Vaughan Carr
Journal:  J Med Internet Res       Date:  2011-01-27       Impact factor: 5.428

Review 6.  Evidence based psychosocial interventions in substance use.

Authors:  Sonali Jhanjee
Journal:  Indian J Psychol Med       Date:  2014-04

7.  Patient satisfaction with treatment for alcohol use disorders: comparing patients with and without severe mental health symptoms.

Authors:  Stacey L McCallum; Jane M Andrews; Matthew D Gaughwin; Deborah A Turnbull; Antonina A Mikocka-Walus
Journal:  Patient Prefer Adherence       Date:  2016-08-04       Impact factor: 2.711

Review 8.  Planning research in psychosocial interventions.

Authors:  Atul Ambekar; Monica Mongia
Journal:  Indian J Psychiatry       Date:  2018-02       Impact factor: 1.759

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.